Once-weekly GLP-1R agonists: Moving the goal posts

Abd A. Tahrani*, Srikanth Bellary, Anthony H. Barnett

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
262 Downloads (Pure)


Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).
Original languageEnglish
Pages (from-to)260-261
JournalThe Lancet Diabetes and Endocrinology
Issue number4
Publication statusPublished - 31 Jan 2018

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Once-weekly GLP-1R agonists: Moving the goal posts'. Together they form a unique fingerprint.

Cite this